IMMUNOVX
Live / Registered — Registered (as of 05 May 2026)
What this means for you
Registered since 05 May 2026. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (next due by 05 May 2032: the §8 declaration of use).
Record
- Serial number
- 98089376
- Registration number
- 8243630
- Mark type
- Word mark
- Filed
- 18 Jul 2023
- Published for opposition
- 11 Feb 2025
- Registered
- 05 May 2026
- Next maintenance filing
- §8 declaration of use, due by 05 May 2032 (grace period to 05 Nov 2032)
- Attorney of record
- Sean P. McConnell
Goods and services
- Class 042 — Scientific and technological services: Clinical research in the field of pharmaceutical, biologic, biotechnology, vaccine, infectious disease treatment, and adjuvant research and development; Research and development and consultation related thereto in the field of pharmaceutical, biologic, biotechnology, vaccine, infectious disease treatment, and adjuvant research and development; Research and development in the pharmaceutical and biotechnology fields; Research and development of new products; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer; Research and development of vaccines and medicines; Research and development services in the field of antibodies; Research, development, engineering and testing services in the fields of immunopharmaceuticals and vaccines; Scientific research; Scientific research consulting; Basic and clinical research in the field of respiratory science and medicine; Biochemical research and development; Consulting services for others in the field of design, planning, and implementation project management of pharmaceutical, biologic, biotechnology, vaccine, infectious disease treatment, and adjuvant research and development; Medical and scientific research in the field of pharmaceutical, biologic, biotechnology, vaccine, infectious disease treatment, and adjuvant research and development; Medical and scientific research, namely, conducting clinical trials for others; Pharmaceutical research and development; Product research and development; Providing information about medical and scientific research; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Scientific research and development; Scientific research in the nature of conducting clinical trials for others in the field of pharmaceutical, biologic, biotechnology, vaccine, infectious disease treatment, and adjuvant research and development
Owner
- Banerjee, Dalfoni, G., Bethlehem, PA, US
- Banerjee, Dalfoni, G., Bethlehem, PA, US
- Banerjee, Dalfoni, G., Conshohocken, PA, US
Prosecution history
- 05 May 2026 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 05 May 2026 — REGISTERED-PRINCIPAL REGISTER
- 13 Apr 2026 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 13 Apr 2026 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 02 Mar 2026 — STATEMENT OF USE PROCESSING COMPLETE
- 25 Aug 2025 — USE AMENDMENT FILED
- 28 Feb 2026 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 25 Aug 2025 — TEAS STATEMENT OF USE RECEIVED
- 08 Apr 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 11 Feb 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 11 Feb 2025 — PUBLISHED FOR OPPOSITION
- 05 Feb 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 22 Jan 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 21 Jan 2025 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
- 20 Jan 2025 — TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS